Recent trends, challenges and future outlook of transdermal drug delivery systems for rheumatoid arthritis therapy

At present, several drug molecules have been used for the treatment of rheumatoid arthritis (RA). However, the utilization of these compounds through the oral and parenteral route is limited due to low bioavailability, rapid metabolism, poor absorption, first-pass effect, and serious adverse effects. A transdermal delivery system is an appealing option in this scenario, as it possesses the proficiency to overcome drawbacks associated with the oral and parenteral route. With the innovation of several enhancement strategies, many therapeutic agents have been administered transdermally, proposing an exceptional approach to treat RA. The present article provides an insight into the etiology and pathophysiology of RA. The challenges of the transdermal route and the strategies to improve those problems are described. The current advances in increasing the transdermal efficiency of the therapeutics against RA are discussed. Limitations and advantages regarding the state of the art transdermal delivery system and future outlook are also summarized. [Display omitted] •Currently, numerous compounds have been used for the treatment of rheumatoid arthritis.•However, the utilization of these compounds through the oral and parenteral route exhibits several limitations.•Transdermal route is an appealing option that not only improves the drug permeation but also enhances patient compliance.•To accelerate the translation from the clinic to market, the safety concerns needs to be evaluated in the very early stage.